

Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis

NCT05455034

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Xinqiao Hospital of Chongqing
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (5)

- Informed consent has been signed, and according to the judgment of the investigator, the patient can comply with the study protocol and sign the written informed consent;
- NSCLC patients who have been clinically diagnosed with RP or CIP after histopathologically confirmed radiotherapy or immuncheckpoint inhibitor treatment and have not received glucocorticoid or other drugs.
- e18years old, less than 75 years old;
- ECOG PS score 0-3 in the Eastern Tumor Collaboration group;
- Patients without contraindications to alveolar lavage;

Exclusion (8)

- Poor patient compliance and violation of test regulations;
- Liver and kidney dysfunction, such as myocardial infarction, angina pectoris, liver transaminase significantly increased;
- Had any medical condition requiring systemic treatment with corticosteroids or other immunosuppressive drugs within 14 days prior to enrollment;
- Severe infection occurred within 4 weeks prior to enrollment, including but not limited to hospitalization due to infection complications, bacteremia or severe pneumonia;
- Severe chronic or active infections (including tuberculosis infection) requiring systemic (oral or intravenous) antibiotic treatment within 14 days prior to enrollment;
- ... and 3 more (see full listing online)

Locations (1 total)

Xinqiao Hospital, Chongqing, Chongqing Municipality, China